Milestone of more than 10’000 views on our policy paper challenging the ICER

Our critical paper “Cost-Utility Analysis: Current Methodological Issues and Future Perspectives:  Frontiers in Pharmacology”  achieved a milestone of more than 10,000 views on September, 2020.

The use of cost–effectiveness as final criterion in the reimbursement process for listing of new pharmaceuticals can be questioned from a scientific and policy point of view. In this review, we focus mainly on only some key methodological concerns relating to discounting, the utility concept, cost assessment, and modeling methodologies. Finally we consider the relevance of some other important decision criteria, like social values and equity.